Environmental risk factors in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 10, Issue 3, 2010, Pages 421-440

  Lauer, Klaus ^a  

^a University Lecturer   (Germany)

Author keywords

Chlamydia pneumoniae; Coronaviruses; Diet; Environmental pollution; Environmental risk factors; Epstein Barr virus; Human herpes virus 6; Interaction with genetic factors; Multiple sclerosis

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CALCITRIOL; FOOD PRESERVATIVE; NITRITE; NITROPHENOL; NITROSAMINE; RECOMBINANT GLYCOPROTEIN GP 120; RITUXIMAB; VALACICLOVIR; VITAMIN D;

AIR POLLUTION; ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; BREAST FEEDING; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONAVIRUS; DIETARY INTAKE; DISEASE TRANSMISSION; ECOLOGY; ELECTROMAGNETIC FIELD; ENTERITIS; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; EXANTHEMA SUBITUM; FAMILY; FISH; FOOD PRESERVATION; FRUIT; HEREDITY; HUMAN; HUMAN HERPESVIRUS 6; HYGIENE; HYPOCALCEMIA; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LIP CANCER; MEAT; MEDITERRANEAN DIET; MICROORGANISM; MOUTH CANCER; MULTIPLE SCLEROSIS; NASOPHARYNX CARCINOMA; NEOPLASM; NONHUMAN; NUTRITION; PHARYNX CANCER; PICORNAVIRUS; PNEUMONIA; POLLUTANT; RETROVIRUS; REVIEW; RISK FACTOR; SEA FOOD; SMOKING; SUN EXPOSURE; ULCERATIVE COLITIS; VARICELLA ZOSTER VIRUS; VEGETABLE; VIRUS INFECTION; VITAMIN D DEFICIENCY; WOOD;

ANIMALS; BREAST FEEDING; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; HERPESVIRUS 4, HUMAN; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; SMOKING; VITAMIN D DEFICIENCY;

EID: 77649281625     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.7     Document Type: Review

References (299)

1. Armstrong BK, White E, Saracci R. Principles of Exposure Measurement in Epidemiology. Oxford University Press, NY, USA (1994).
2. MacMahon B, Trichopoulos D. Epidemiology: Principles and Methods. Lippincott Williams and Wilkins, PA, USA (1996).
3. Kleinbaum DG, Kupper LL. Epidemiologic Research. Van Nostrand Reinhold, NY, USA (1982).
4. Kelsey JL, Thompson WD, Evans AS. Methods in Observational Epidemiology. Oxford University Press, NY, USA (1986).
5. Hennekens CH, Buring JE, Mayrent SC. Epidemiology in Medicine. Little, Brown and Co., MA, USA (1987).
6. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Lippincott Williams and Wilkins, PA, USA (2008).
7. Rothman KJ. Epidemiology. An Introduction. Oxford University Press, Oxford, UK (2002).
8. Morgenstern H. Ecological studies. In: Modern Epidemiology. Rothman KJ, Greenland S (Eds). Lippincott Williams and Wilkins, PA, USA, 459-480 (1998).
9. Feinstein AR. Clinical Epidemiology. The Architecture of Clinical Research. WB Sauders, PA, USA (1985).
10. Pearce N. Traditional epidemiology, modern epidemiology, and public health. Am. J. Publ. Health 86, 678-683 (1996).
11. Lauer K. [The epidemiology of multiple sclerosis]. In: [The inflammatory diseases of the central nervous system]. 3rd Supplementation, 2/97. Henkes HG, Koelmel HW (Eds). EcoMed, Germany 1-86 (1997).
12. Kantarci OH. Genetics and natural history of multiple sclerosis. Semin. Neurol. 28, 7-16 (2008).
13. Ramagopalan SV, Dyment DA, Ebers GC. Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci. 31, 645-652 (2008).
14. Oksenberg JR, Hauser SL. Genetics of multiple sclerosis. In: Multiple Sclerosis: a Comprehensive Text. Raine CS, McFarland HF, Hohlfeld R (Eds). Saunders, Edinburgh, UK, 214-225 (2008).
15. Kuusisto H, Kaprio J, Kinnunen E, Luukkaala T, Koskenvuo M, Elovaara I. Concordance and heretability of multiple sclerosis in Finland: study on a nationwide series of twins. Eur. J. Neurol. 15, 1106-1110 (2008).
16. The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357, 851-862 (2007).
17. Lundmark F, Duvegelt K, Iacobaeus E et al. Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39, 1108-1113 (2007).
18. Murrell TG, Harbige LS, Robinson IC. A review of the aetiology of multiple sclerosis: an ecological approach. Ann. Hum. Biol. 18, 95-112 (1991).
19. Granieri E. Exogenous factors in the aetiology of multiple sclerosis. J. Neurovirol. 6 (Suppl. 2), 141-146 (2000).
20. Coo H, Aronson KJ. A systematic review of several potential non-genetic risk factors for multiple sclerosis. Neuroepidemiology 23, 1-12 (2004).
21. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 3, 709-718 (2004).
22. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis.: new insights. Curr. Opin. Neurol. 19, 248-254 (2006).
23. Giovannoni G, Ebers GC. Multiple sclerosis: the environment and causation. Curr. Opin. Neurol. 20, 261-268 (2007).
24. Pugliatti M, Harbo HF, Holmøy T et al. Environmental risk factors in multiple sclerosis. Acta Neurol. Scand. Suppl. 188, 34-40 (2008).
25. Pugliatti M, Rosati G. Epidemiology of multiple sclerosis. In: Multiple Sclerosis: a Comprehensive Text. Raine CS, McFarland HF, Hohlfeld R (Eds). Saunders, Edinburgh, UK, 121-140 (2008).
26. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288-299 (2007).
27. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: non-infectious factors. Ann. Neurol. 61, 504-513 (2007).
28. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1, 43-46 (1990).
29. Savitz DA, Olshan AF. Multiple comparisons and related issues in the interpretation of epidemiological data. Am. J. Epidemiol. 142, 904-908 (1995).
30. Ascherio A, Munger K. Epidemiology of multiple sclerosis: from risk factors to prevention. Sem. Neurol. 28, 17-28 (2008).
31. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology 67, 2085-2086 (2006).
32. Sotgiu S, Angius A, Embry A, Rosati G, Musumeci S. Hygiene hypothesis: innate immunity, malaria and multiple sclerosis. Med. Hypotheses 70, 819-825 (2008).
33. Nielsen NM, Wohlfahrt J, Melbye M et al. Multiple sclerosis and poliomyelitis. A Danish historical cohort study. Acta Neurol. Scand. 101, 384-387 (2000).
34. Leibowitz U, Antonovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple sclerosis in Israel. Part II. Multiple sclerosis and level of sanitation. J. Neurol. Neurosurg. Psychiatry 29, 60-68 (1966).
35. Beebe GW, Kurtzke JF, Kurland LT, Auth TL, Nagler B. Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the army experience in World War II. Neurology 17, 1-17 (1967).
36. Russell WR. Multiple sclerosis: occupation and social group at onset. Lancet 2, 832-834 (1971).
37. Hammond SR, Mc Leod JG, Macaskill P, English DR. Multiple sclerosis in Australia: socioeconomic factors. J. Neurol. Neurosurg. Psychiatry 61, 311-313 (1996).
38. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann. Neurol. 61, 97-108 (2007).
39. Alter M, Xin ZZ, Davanipour Z, Sobel E, Min Lai S, LaRue L. Does delay in acquiring childhood infection increase risk of multiple sclerosis? Ital. J. Neurol. Sci. 8, 73-74 (1987).
40. Niederman JC, Evans AS. Epstein-Barr virus. In: Viral Infections of Humans: Epidemiology and Control. Evans AS, Kaslow RA (Eds). Plenum Medical Book Company, NY, USA, 253-283 (1997).
41. Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 10, 62-65 (1991).
42. Haahr S, Koch-Henriksen N, Möller-Larsen A, Eriksen LS, Andersen HMK. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult. Scler. 1, 73-77 (1995).
43. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Multiple sclerosis after infectious mononucleaosis: record linkage study. J. Epidemiol. Community Health 58, 1032-1035 (2004).
44. Pejme J. Infectious mononucleosis. A clinical and haematological study of patients and contacts, and a comparison with healthy subjects. Acta Med. Scand. 175(Suppl. 413), 1-83 (1964).
45. Portegies P, Corssmit N. Epstein-Barr virus and the nervous system. Curr. Opin. Neurol. 13, 301-304 (2000).
46. Granieri E, Casetta I. Common childhood and adolescent infections and multiple sclerosis. Neurology 49(Suppl. 2), S42-S54 (1997).
47. Levin LI Munger KL, Rubertone MV et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms of multiple sclerosis. JAMA 293, 2496-2500 (2005).
48. Ascherio A, Munger KL, Lennette ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis. JAMA 286, 3083-3088 (2001).
49. DeLorenze GN, Munger KL, Lennette E et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63, 839-844 (2006).
50. Sundström P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis. A prospective study. Neurology 62, 2277-2282 (2004).
51. Luenemann JD, Edwards N, Muraro PA et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-I-specific T cells in multiple sclerosis. Brain 129, 1493-1506 (2006).
52. Luenemann JD, Jelcic I, Roberts S et al. EBNA1-specific T cells from patients with multiplesclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2. J. Exp. Med. 205, 1763-1773 (2008).
53. Cepok S, Zhou D, Srivastava R et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 115, 1352-1360 (2005).
54. Rumpold H, Rhodes GH, Bloch PL, Carson DA, Vaughan JH. The glycine-alanine repeating region is the major epitope of the Epstein-Barr nuclear antigen-1 (EBNA-1). J. Immunol. 138, 593-599 (1987).
55. Dromey JA, Weenink SM, Peters GH et al. Mapping of epitopes for autoantibodies to the type-1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J. Immunol. 172, 4084-4090 (2004).
56. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis JAMA 291, 1875-1879 (2004).
57. Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67, 2063-2065 (2006).
58. Barzilai O, Sherer Y, Ram M, Izhaky D, Anaya JM, Shoenfeld Y. Epstein-Barr virus and cytomegalovirus in autoimmune diseases. Ann. NY Acad. Sci. 1108, 567-577 (2007).
59. Lang HL, Jacobsen H, Ikemizu S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3, 940-943 (2002).
60. Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899-2912 (2007).
61. Maggiore G, Trillo-Pazos G, Reynolds R, Giovannoni D, Miller D. Detection of EBV antigens in germinal centres in the brain of people with multiple sclerosis. J. Neurol. 255(Suppl. 2), 9 (2008).
62. Morré SA, van Beek J, De Groot CJ et al. Is Epstein-Barr virus present in the CNS of patients with MS? Neurology 56, 692 (2001).
63. Sanders VJ, Felison S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J. Neurovirol. 2, 249-258 (1996).
64. Opsahl ML, Kennedy PGE. An attempt to investigate the presence of Epstein-Barr virus in multiple sclerosis and normal control brain tissue. J. Neurol. 254, 425-430 (2007).
65. Dean G, Kurtzke JF. On the risk of multiple sclerosis according to age at immigration to South Africa. Br. Med. J. 3, 725-729 (1971).
66. Kurtzke JF, Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome. J. Clin. Epidemiol. 54, 1-22 (2001).
67. Pender MP. Preventing and curing multiple sclerosis by controlling Epstein-Barr virus infection. Autoimmun. Rev. 8, 563-568 (2009).
68. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499-503 (2006).
69. Challoner PB, Smith KT, Parker JD et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc. Natl Acad. Sci. USA 92, 7440-7444 (1995).
70. Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS 109, 401-411 (2001).
71. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann. Neurol. 53, 189-197 (2003).
72. Clark D. Human herpesvirus type 6 and multiple sclerosis. Herpes 11(Suppl. 2), 112A-119A (2004).
73. Álvarez-Lafuente R, García-Montojo M, de las Heras V et al. Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Mult. Scler. 14, 595-601 (2008).
74. Sundström P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis. A prospective study. Neurology 62, 2277-2281 (2004).
75. Lycke J, Svennerholm B, Hjelmquist E et al. Acyclovir treatment of relapsingremitting multiple sclerosis. A randomized placebo-controlled, double-blind study. J. Neurol. 243, 214-224 (1996).
76. Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 58, 31-36 (2002).
77. Tanaka R, Iwasaki Y, Koprowski H. Intracisternal virus-like particles in brain of a multiple sclerosis patient. J. Neurol. Sci. 28, 121-126 (1976).
78. Burks JS, DeVald BL, Jankovsky LD, Gerdes JC. Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients. Science 209, 933-934 (1980).
79. Salmi A, Ziola B, Hovi T, Reunanen M. Antibodies to coronaviruses OC43 and 229E in multiple sclerosis patients. Neurology 32, 292-295 (1982).
80. Murray RS, Brown B, Brian D, Cabirac GF. Detection of coronavirus RNA and antigen in multiple sclerosis brain. Ann. Neurol. 31, 525-533 (1992).
81. Stewart JN, Mounir S, Talbot PJ. Human coronavirus gene expression in the brains of multiple sclerosis patients. Virology 191, 502-505 (1992).
82. Arbour N, Day R, Newcombe J, Talbot PJ. Neuroinvasion by human respiratory coronaviruses. J. Virol. 74, 8913-8921 (2000).
83. Dessau RB, Frederiksen JL. Coronaviruses in brain tissue from patients with multiple sclerosis. Eur. J. Neurol. 7(Suppl. 3), 94 (2000).
84. Talbot PJ, Paquette JS, Ciurli C, Antel J, Quellet F. Myelin basic protein and human coronavirus 229E cross-reactive T cells in multipler sclerosis. Ann. Neurol. 39, 233-240 (1996).
85. Boucher A, Desforges M, Duquette P, Talbot PJ. Long-term human coronavirusmyelin cross-reactive T cell clones derived from multiple sclerosis patients. Clin. Immunol. 123, 258-267 (2007).
86. Jouvenne P, Mounir S, Stewart JN, Richardson CD, Talbot PJ. Sequence analysis of human coronavirus 229E mRNAs 4 and 5: evidence for polymorphism and homology with myelin basic protein. Virus Res. 22, 125-141 (1992).
87. Cristallo A, Gambaro F, Ferrante P, Battaglia M, Sereda PM. Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients. New Microbiol. 20, 105-114 (1997).
88. Edwards JA, Denis F, Talbot PJ. Activation of glial cells by human coronavirus OC43 infection. J. Neuroimmunol. 108, 73-81 (2000).
89. Dolei A, Perron H. The multiple sclerosis-associated retrovirus and its HERV-W endogenous family: a biological interface between virology, genetics, and immunology in human physiology and disease. J. Neurovirol. 15, 4-13 (2009).
90. Christensen T, Jensen AW, Munch M et al. Characterization of retrovirus from patients with multiple sclerosis. Acta Neurol. Scand. Suppl. 169, 49-58 (1997).
91. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev. Med. Virol. 15, 179-211 (2005).
92. Oleszak EL, Chang JR, Friedman H, Katsetos CD, Platsoucas CD. Theiler's virus infection: a model for multiple sclerosis. Clin. Microbiol. Rev. 17, 174-207 (2004).
93. Chiu CY, Greninger AL, Kanada K et al. Identification of cardioviruses related to Theiler's murine encephalomyelitis virus in human infections. Proc. Natl Acad. Sci. USA 105, 14124-14129 (2008).
94. Blinkova O, Kapoor A, Victoria J et al. Cardioviruses are genetically diverse and cause common enteric infections in south Asian children. J. Virol. 83, 4631-4641 (2009).
95. Ross RT, Cheang M. Geographic similarities between varicella and multiple sclerosis: an hypothesis on the environmental factor of multiple sclerosis. J. Clin. Epidemiol. 48, 731-732 (1995).
96. Ross RT, Nicolle LE, Cheang M. Varicella zoster virus and multiple sclerosis in a Hutterite population. J. Clin. Epidemiol. 48, 1319-1324 (1995).
97. Compston DA, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Muns CA. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 109, 325-344 (1986).
98. Sullivan CB, Visscher BR, Detels R. Multiple sclerosis and age at exposure to childhood diseases and animals: cases and their friends. Neurology 34, 1144-1148 (1984).
99. Rodríguez-Violante M, Ordoñez G, Ramirez Bermudez J, Sotelo J, Corona T. Association of a history of varicella virus infection with multiple sclerosis. Clin. Neurol. Neurosurg. 111, 54-56 (2009).
100. Mikaeloff Y, Cariade G, Suissa S, Tardieu M for the KIDSEP Study Group. Clinically observed chickenpox and the risk of childhood-onset multiple sclerosis. Am. J. Epidemiol. 169, 1260-1266 (2009).
101. Sriram S, Stratton CW, Yao S et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann. Neurol. 46, 6-14 (1999).
102. Layh-Schmitt G, Bendl C, Hildt U et al. Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis. Ann. Neurol. 47, 652-655 (2000).
103. Gieffers J, Pohl D, Treib J et al. Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis. Ann. Neurol. 49, 585-589 (2001).
104. Boman J, Roblin PM, Sundström P, Sandström M, Hammerschlag MR. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS. Neurology 54, 265 (2000).
105. Treib J, Haass A, Stille W et al. Multiple sclerosis and Chlamydia pneumoniae. Ann. Neurol. 47, 408 (2000).
106. Bagos PG, Nikolopoulos G, Ioannidis A. Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult. Scler. 12, 397-411 (2006).
107. Kaufman M, Gaydos CA, Sriram S, Boman J, Tondella ML, Norton HJ. Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results. Mult. Scler. 8, 289-294 (2002).
108. Karvonen M, Tuomilehto J, Pitkäniemi J, Naukkarinen A, Saikku P. Importance of smoking for Chlamydia pneumoniae seropositivity. Int. J. Epidemiol. 23, 1315-1321 (1994).
109. Contini C, Cultrera R, Seraceni S, Castellazzi M, Granieri E, Fainardi E. Cerebrospinal fluid-molecular demonstration of Clamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult. Scler. 10, 360-369 (2004).
110. Munger KL, Peeling RW, Hernán MA et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology 14, 141-147 (2003).
111. Munger KL, DeLorenzo GN, Levin LI et al. A prospctive study of Chlamydia pneumoniae infection and rik of MS in two US cohorts. Neurology 62, 1799-1803 (2004).
112. Derfuss D, Gurkov R, Then Berg F et al. Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 124, 1325-1335 (2001).
113. Lauer K. [Descriptive and analytical studies on the epidemiology of multiple sclerosis in the area of southern Hesse]. Thesis, Frankfurt, Germany (1993).
114. Hernán MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A. Multiple sclerosis and age at infection with common viruses. Epidemiology 12, 301-306 (2001).
115. Bager P, Nielsen NM, Bihrmann K et al. Childhood infections and risk of multiple sclerosis. Brain 127, 2491-2497 (2004).
116. Lauer K. Environmental associations with the risk of MS: the contribution of ecological studies. Acta Neurol. Scand. Suppl. 161, 77-88 (1995).
117. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation and other variables. Acta Neurol. Scand. Suppl. 35(Suppl. 147), 132-147 (1960).
118. Norman JE, Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in U.S. veterans. 2. Latitude, climate, and the risk of multiple sclerosis. J. Chronic Dis. 136, 551-559 (1983).
119. Sutherland JM, Tyrer JH, Eadie MJ. The prevalence of multiple sclerosis in Australia. Brain 85, 149-164 (1962).
120. van der Mei IAF, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168-174 (2001).
121. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol. 7, 268-277 (2008).
122. Georgi F, Hall P. Studies on multiple sclerosis frequency in Switzerland and East Africa. Acta Neurol. Scand. Suppl. 35 (Suppl. 147), 75-84 (1960).
123. Freedman DM, Dosemeci M, Alavanja MCR. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup. Environ. Med. 57, 418-421 (2000).
124. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J. Epidemiol. Community Health 58, 142-144 (2004).
125. Cendrowski W, Wender M, Dominik W, Flejsierowicz Z, Owsianowski M, Popiel M. Epidemiological study of multiple sclerosis in Western Poland. Eur. Neurol. 2, 90-108 (1969).
126. Antonovsky A, Leibowitz U, Smith HA et al. Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch. Neurol. 13, 183-193 (1965).
127. van der Mei IAF, Ponsonby A-L, Dwyer T et al. Past expopsure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 327, 316-320 (2003).
128. Kampman MT, Wilsgaard F, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 254, 471-477 (2007).
129. Islam T, Gauderman WJ, Cozen W, Mack TM. Childhood sun exposure influences risk of multiple sclerosis in monozygotic twins. Neurology 69, 381-388 (2007).
130. Duthie MS, Kinber I, Norval M. The effects of ultraviolet radiation on the immune system. Br. J. Dermatol. 140, 995-1009 (1999).
131. Constantinescu CS. Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Med. Hypotheses 45, 455-458 (1995).
132. Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: Sunlight, dietary factors and epidemiology. Int. J. Environ. Stud. 6, 19-27 (1974).
133. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44, 1687-1692 (1994).
134. Ozgogmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 23, 309-313 (2005).
135. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A. 25-hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11, 266-271 (2005).
136. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 79, 152-157 (2008).
137. Barnes MS, Bonham MP, Robson PJ et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple sclerosis patients and control volunteers. Mult. Scler. 13, 670-672 (2007).
138. van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 254, 581-590 (2007).
139. Kragt JJ, van Amerongen BM, Killestein J et al. Higher level of 25-hyroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult. Scler. 15, 9-15 (2009).
140. Orton SM, Morris AP, Herrera BM et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am. J. Clin. Nutr. 88, 441-447 (2008).
141. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60-65 (2004).
142. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006).
143. Hayes CE, Cantorna MT, Deluca HF. Vitamin D and multiple sclerosis. Proc. Soc. Exp. Biol. Med. 216, 21-27 (1997).
144. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. 229, 1136-1142 (2004).
145. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis. J. Neuroimmunol. 194, 7-17 (2008).
146. Cantorna MT, Hayes CE, De Luca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progressioon of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl Acad. Sci. USA 93, 7861-7864 (1996).
147. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-Grand) 49, 277-300 (2003).
148. Rao M, Goswami R, Gupta N, Ray D, Tandon N, Kumar N. Prevalence and functional significance of 25-hydroxyvitamin D deficiency and vitamin D receptor gene polymorphism in Asian Indians. Am. J. Clin. Nutr. 83, 1411-1419 (2006).
149. Goswami R, Mishra SK, Kochupillai N. Prevalence and potential significance of vitamin D deficiency in Asian Indians. Indian J. Med. Res. 127, 229-238 (2008).
150. Goswami R, Marwaha RK, Gupta N et al. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br. J. Nutr. 102, 382-386 (2009).
151. Bharucha NE. Bharucha EP, Wadia NH et al. Prevalence of multiple sclerosis in the Parsis of Bombay. Neurology 38, 727-729 (1988).
152. Singhal BS. Multiple sclerosis and related demyelinating disorders in Indian context. Neurol. India 35, 1-12 (1987).
153. Gourie-Devi M, Gururaj G, Satishchandra P, Subbakrishna DK. Prevalence of neurological disorders in Bangalore, India: a community-based study with a comparison between urban and rural areas. Neuroepidemiology 23, 261-268 (2004).
154. Brustad M, Randanger T, Wilsgaard T, Aksnes L, Lund E. Change in plasma levels of vitamin D after consumption of cod-liver and fresh cod-liver oil as part of the traditional north Norwegian fish dish 'Mølje'. Int. J. Circumpolar Health 62, 40-53 (2003).
155. Kurtzke JF. Epidemiology and etiology of multiple sclerosis. Phys. Med. Rehabil. Clin. N. Am. 16, 327-349 (2005).
156. Oliveri B, Plantalech L, Wittich AC et al. High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina. Eur. J. Clin. Nutr. 58, 337-342 (2004).
157. Melcon MO, Gold L, Carrá C et al. Argentine Patagonia: prevalence and clinical features of multiple sclerosis. Mult. Scler. 14, 656-662 (2008).
158. Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical hisatory factors and multiple sclerosis. Can. J. Pubic Health 92, 281-285 (2001).
159. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 61, 1122-1124 (2003).
160. Pekmezovic T, Drulovic J, Milenkovic M et al. Lifestyle factors and multiple sclerosis: a case-control study in Belgrade. Neuroepidemiology 27, 212-216 (2006).
161. Hedström AK, Bäärnhjelm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 73, 696-701 (2009)
162. Sundström P, Nyström P, Hallmans G. Smoke exposure increases the risk for multiple sclerosis. Eur. J. Neurol. 15, 579-583 (2008).
163. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 128, 1461-1465 (2005).
164. Hernán MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 154, 69-74 (2001).
165. Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception 47, 161-168 (1993).
166. Casetta I, Granieri E, Malagu S et al. Environmental risk factors and multiple sclerosis: A community-based study in the province of Ferrara, Italy. Neuroepidemiology 13, 120-128 (1994).
167. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol. 105, 1296-1299 (1998).
168. Hawkes CH. Smoking is a risk factor for multiple sclerosis: a metanalysis. Mult. Scler. 13, 610-615 (2007).
169. Mikaeloff Y, Caridade G, Tardieu M, Suissa S for the KIDSEP study group. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130, 2589-2595 (2007).
170. Montgomery SM, Bahmanyar S, Hillert J, Ekbom A, Olsson T. Maternal smoking during pregnancy and multiple sclerosis amongst offspring. Eur. J. Neurol. 15, 1395-1399 (2008).
171. Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology 69, 1515-1520 (2007).
172. Di Pauli F, Reindl F, Ehling R et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult. Scler. 14, 1026-1030 (2008).
173. Sundstöm P, Nyström L. Smoking worsens the prognosis in multiple sclerosis. Mult. Scler. 14, 1031-1035 (2008).
174. Pittas F, Ponsonby A-L, van der Mei I et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J. Neurol. 256, 577-585 (2009).
175. Zivadinov R, Weinstock-Guttman B, Hashimi K et al. Smoking is associated with increased lesion volume and brain atrophy in multiple sclerosis. Neurology 73, 504-510 (2009).
176. Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 83, 148-156 (1998).
177. McCoy EC, Rosenkranz HS. Cigarette smoking may yield nitroarenes. Cancer Lett. 15, 9-13 (1982).
178. Schlemitz S, Pfannhauser W. Analysis of nitro-PAHs in food matrices by on-line reduction and high performance liquid chromatography. Food Addit. Contam. 13, 969-977 (1996).
179. Schlemitz S, Pfannhauser W. Monitoring of nitropolycyclic aromatic hydrocarbons in food using gas chromatography. Z. Lebensm. Unters. Forsch. 203, 61-64 (1996).
180. Berr C, Puel J, Clanet M, Ruidavets JB, Mas JL, Aperovitch A. Risk factors in multipler sclerosis: a population-based case-control study in Hautes-Pyrénées, France. Acta Neurol. Scand. 80, 46-50 (1989).
181. Spenceley M, Dick G. Breast-feeding and multiple sclerosis. Neuroepidemiology 1, 216-222 (1982).
182. Pisacane A, Impagliazzo N, Russo M et al. Breast feeding and multiple sclerosis. Br. Med. J. 308, 1411-1412 (1994).
183. Tarrats R, Ordoñez G, Rios C, Sotelo J. Varicella, ephermal breastfeeding and eczema as risk factors for multiple sclerosis in Mexicans. Acta Neurol. Scand. 105, 88-94 (2002).
184. Jackson KM, Nazar AM. Breastfeeding, the immune response, and long-term health. J. Am. Osteopath. Assoc. 106, 203-207 (2006).
185. Knip M, Akerblom HK. Early nutrition and later diabetes risk. Adv. Exp. Med. Biol. 569, 142-150 (2005).
186. Liao KP, Alfredsson L, Karlson EW. Environmental influences on risk for rheumatoid arthritis. Curr. Op. Rheumatol. 21, 279-283 (2009).
187. Rosenberg KD, McMurtrie C, Kerker BD, Na Y, Graham EH. Breast-feeding initiation in New York city, 1979-1996. Am. J. Public Health 88, 1850-1852 (1998).
188. Langer-Gould A, Huang SM, Leimpeter AD, Albers KB, van den Eeden SK, Nelson LM. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch. Neurol. 66, 958-963 (2009).
189. Seyfert S, Klapps P, Meisel C, Fischer T, Junghans C. Multiple sclerosis and other immunologic diseases. Acta Neurol. Scand. 81, 37-42 (1990).
190. Kirby S, Brown MG, Murray TJ, Fisk JD, Stadnyk K, MacKinnon-Cameron D, Bhan V. Prevalence of other autoimmune diseases in patients with multiple sclerosis. Mult. Scler. 11(Suppl. 1), 29 (2005).
191. Gilani A, Robertson K, Lindzen E, Mann JD. Prevalence of comorbid autoimmune disease in a cohort of 66 multiple sclerosis ambulatory clinic patients. Neurology 62(Suppl. 5), 224-225 (2004).
192. Barcellos LF, Kamdar BD, Ramsay PP et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 5, 924-931 (2006).
193. Nielsen N, Frisch M, Rostgaard K et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult. Scler. 14, 823-829 (2008).
194. Pugliatti M, Sotgiu S, van Duijn CM, Rosati G. Recurrence of immuno-mediated disorders among relatives of multiple sclerosis patients in Sardinia. Mult. Scler. 4, 370 (1998).
195. Hemminki K, Li X, Sundquist J, Sundquist K. Familial risks for amyotrophic lateral sclerosis and autoimmune diseases. Neurogenetics 10, 111-116 (2009).
196. Purrmann J, Arendt G, Cleveland S et al. Association of Crohn's disease and multiple sclerosis. Is there a common background? J. Clin. Gastroenterol. 14, 43-46 (1992).
197. Rang EH, Brooke BN, Hermon Taylor J. Association of ulcerative colitis with multiple sclerosis. Lancet 2, 555 (1982).
198. Minuk GY, Lewkonia RM. Possible familial association of multiple sclerosis and inflammatory bowel disease. N. Engl. J. Med. 314, 586 (1986).
199. Yacyshyn B, Meddings J, Sadowski D, Bowen-Yacyshyn MB. Multiple sclerosis patients have peripheral blood CD45R0 B cells and increased intestinal permeability. Dig. Dis. Sci. 41, 2493-2498 (1996).
200. Geissler A, Anders T, Roth M et al. Focal white matter lesions in brain of patients with inflammatory bowel disease. Lancet 345, 897-898 (1995).
201. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129, 819-826 (2005).
202. Bernstein CN, Wadja A, Blachard JF. The clustering of other inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129, 827-836 (2005).
203. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a Northern California-managed care organization. Am. J. Gastroenterol. 102, 1-7 (2007).
204. Langer-Gould A, Albers KB, van den Eeden SK, Nelson LM. Comorbid autoimmune and allergic conditions in multiple sclerosis: a comprehensive population-based case-control study. Mult. Scler. 14 (Suppl.1), 188 (2008).
205. Wertmann E, Zilber N, Abramsky O. An association between multiple sclerosis and type I diabetes mellitus. J. Neurology 239, 43-45 (1992).
206. Arpa J, Muñoz-Torrero J, Gonzáles J et al. Multiple sclerosis and type I diabetes mellitus. Eur. J. Neurol. 3(Suppl. 5), 107 (1996).
207. Milonas I, Bairaktaris C, Danilides M, Iakovidou E, Grigoriadis N, Tsounis S. Coexistence of multiple sclerosis and insulin-dependent diabetes mellitus (Type 1). Mult. Scler. 3, 323 (1997).
208. Cocco E, Sardu C, Lai M, Spinicci G, Contu P, Marrosu MG. Anticipation of age at onset in multiple sclerosis. A Sardinian cohort study. Neurology 62, 1794-1798 (2004).
209. Marrosu M, Cocco E, Lai M, Spinicci G, Pischedda MP, Contu P. Patients with multiple sclerosis and risk of Type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 359, 1461-1465 (2001).
210. Russel MG, Stockbruegger RW. Epidemiology of inflammatory bowel disease: an update. Scand. J. Gastroenterol. 31, 417-427 (1996).
211. Tragnone A, Valpiani D, Miglio F et al. Dietary habits as risk factors for inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 7, 47-51 (1995).
212. Jowett SL, Seal CJ, Pearce MS et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 53, 1479-1484 (2004).
213. Lauer K. Inflammatory bowel disease: lessons from animal models. Am. J. Gastroenterol. 103, 802 (2008).
214. Dahlquist GG. Viruses and other perinatal exposures as initiating events for β-cell destruction. Ann. Med. 29, 413-417 (1997).
215. Dorman JS. Molecular epidemiology of insulin-dependent diabetes mellitus. Epidemiol. Rev. 19, 91-98 (1997).
216. Dahlquist G. The aetiology of Type-1 diabetes: an epidemiological perspective. Acta Paediatr. Suppl. 425, 5-10 (1998).
217. Dahlquist GG, Blom LG, Persson L-Å, Sandström AIM, Wall SGI. Dietary factors and the risk of developing insulin dependent diabetes in childhood. Br. Med. J. 300, 1302-1306 (1990).
218. Helgason T, Jonasson MR. Evidence for a food additive as cause of ketosis-prone diabetes. Lancet 2, 716-720 (1981).
219. Helgasson T, Ewen SW, Ross IS, Stowers JM. Diabetes produced in mice by smoked/cured mutton. Lancet 2, 1017-1022 (1982).
220. Virtanen SM, Jaakkola L, Räsänen L et al. Nitrate and nitrite intake and the risk for type-1 diabetes in Finnish children. Chidhood Diabetes in Finland Study Group. Diabetes Med. 11, 656-662 (1994).
221. Palo J, Duchesne J, Wikström J. Malignant diseases among patients with multiple sclerosis. J. Neurol. 216, 217-222 (1977).
222. Lebrun C, Debouverie M, Vermersch P et al. for le Club Francophone de la Sclérose en Plaque (CFSEP). Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult. Scler. 14, 399-405 (2008).
223. Lauer K. [The risk of malignancy in multiple sclerosis patients in comparison with the general population: prospective data from a regional registry]. Gesundheitswesen 57, 590 (1995).
224. Materljan E, Materljan M, Materljan B, Vlačić H, Barićev-Novaković Z, Sepčic J. Multiple sclerosis and cancers in Croatia. A possible protective role of the 'Mediterranean Diet'. Coll. Antropol. 33, 539-545 (2009).
225. Darmstaedter E. The mortality of multiple sclerosis 1975-1995 in the State of Lower Saxony, northern Germany. Mult. Scler. 14, 189 (2008).
226. Bellian KT, Devlin PM, Zimmer CA, Powell DM, Matticks CA, Edlich RF. Concurrence of multiple sclerosis and Hodgkin's disease. J. Emerg. Med. 10, 13-18 (1992).
227. Hjalgrim H, Rasmussen S, Rostgaard K et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J. Natl Cancer Inst. 96, 780-784 (2004).
228. Vineis P, Crosignani P, Viganò C et al. Lymphomas and multiple sclerosis in a multicenter case-control study. Epidemiology 12, 134-135 (2001).
229. Zhang Y, Holford TR, Leasderer B et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in connecticut United States women. Cancer Causes Control 15, 419-428 (2004).
230. Smedby KE, Vajdic CM, Falster M et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111, 4029-4038 (2008).
231. Møller H, Kneller RW, Boice JD, Olsen JH. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta Neurol. Scand. 84, 214-220 (1991).
232. Nielsen NM, Rostgaard K, Rasmussen S et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int. J. Cancer 118, 979-984 (2006).
233. Auwaerter PG. Recent advances in the understanding of infectious mononucleosis: are prospects improved for treatment or control? Expert Rev. Anti Infect. Ther. 4, 1039-1049 (2006).
234. Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol. Pathol. 53, 262-269 (2000).
235. Wolfgram F. Similar geographical distribution of multiple sclerosis and cancer of the colon. Acta Neurol. Scand. 52, 294-302 (1975).
236. Lauer K. The distribution of multiple sclerosis and 7 malignancies: a comparison in 12 regions. Schweiz. Arch. Neurol. Psychiatr. 144, 348 (1993).
237. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their patents. Neurology 72, 1170-1177 (2009).
238. Langer-Gould A, Albers KB, Nelson LM, van den Eeden SK. Prevalence of vitamin D-, herpes-virus family and hormonally-related diseases in multiple sclerosis: a comprehensive population-based case-control study. Mult. Scler. 14(Suppl. 1), 188 (2008).
239. Schuetz J, Waldemar G, Olsen JH, Johansen C. Risk for central nervous system disease among phone subscribers: a Danish retrospective cohort study. PloS One 4(2), e4389 (2009).
240. Feyching M, Jonsson F, Pedersen NL, Ahlbom A. Occupational magnetic field exposure and neurodegenerative disease. Epidemiology 14, 413-419 (2003).
241. Johansen C, Koch-Henriksen N, Rasmussen S, Olsen JH. Multiple sclerosis among utility workers. Neurology 52, 1279-1282 (1999).
242. Röösli M, Lörtscher M, Egger M et al. Mortality from neurodegenerative disease and exposure to extremely low-frequency magnetic fields: 31 years of observations on Swiss railway employees. Neuroepidemiology 28, 197-206 (2007).
243. Huss A, Spoerri A, Egger M, Röösli M; for the Swiss National Cohort Study. Residence near power lines and mortality from neurodegenerative diseases: longitudinal study of the Swiss population. Am. J. Epidemiol. 169, 167-175 (2009).
244. World Health Organization. Extremely Low Frequency Fields, Environmental Health Criteria 238. World Health Organization, Geneva, Switzerland (2007).
245. Gregory AC, Shendell DG, Okosun IS, Gieseker KE. Multiple sclerosis disease distribution and potential impact of environmental air pollutants in Georgia. Sci. Total Environ. 396, 42-51 (2008).
246. Oikonen M, Laaksonen M, Laippala P et al. Ambient air quality and occurrence of multiple sclerosis relapse. Neuroepidemiology 22, 95-99 (2003).
247. Oikonen MK, Erälinna J-P. β-interferon protects multiple sclerosis patients against enhanced susceptibility to infections caused by poor air quality. Neuroepidemiology 30, 13-19 (2008).
248. Ma JYC, Ma JKH. The dual effect of the particulate and organic components of diesel exhaust particles on the alteration of pulmonary immune/inflammatory responses and metabolic enzymes J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. C20, 117-147 (2002).
249. Barth SK, Kang HK, Bullman TA, Wallin MT. Neurological mortality among U.S. veterans of the Persian Gulf War: 13-year follow-up. Am. J. Ind. Med. 52, 663-670 (2009).
250. Sanderson IR, Walker WA. Uptake and transportation of macromolecules by the intestine: possible role in clinical disorders (an update). Gastroenterology 104, 622-639 (1993).
251. Alter M, Yamoor M, Harshe M. Multiple sclerosis and nutrition. Arch. Neurol. 31, 267-272 (1974).
252. Knox EG. Foods and diseases. Br. J. Prev. Soc. Med. 31, 71-80 (1977).
253. Swank R, Lerstad O, Strøm A, Backer J. Multiple sclerosis in rural Norway. Its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 246, 721-728 (1952).
254. Lauer K. Nutrition and multiple sclerosis. Mult. Scler. 12(Suppl. 1), 133 (2006).
255. Nanji AA, Narod S. Multiple sclerosis, latitude and dietary fat: is pork the missing link? Med. Hypotheses 20, 279-282 (1986).
256. Lauer K. Dietary changes in temporal relation to multiple sclerosis in the Faroe Islands. An evaluation of literary sources. Neuroepidemiology 8, 200-206 (1989).
257. Lauer K. Multiple sclerosis in relation to meat preservation in France and Switzerland. Neuroepidemiology 8, 308-315 (1989).
258. Lauer K. The Fennoscandian focus of multiple sclerosis and dietary exposures: an ecological comparison. L'Arcispedale S. Anna di Ferrara 46(Suppl.), 17-18 (1996).
259. Lauer K. Sausage preservation methods and the prevalence of multiple sclerosis: an ecological study. Ecol. Food Nutr. 46, 1-11 (2007).
260. Gusev E, Boiko A, Lauer K, Riise T, Deomina T. Environmental risk factors in MS: a case-control study in Moscow. Acta Neurol. Scand. 94, 386-394 (1996).
261. Zorzon M, Zivadinov R, Nasuelli D et al. Risk factors of multiple sclerosis: a case-control study. Neurol. Sci. 24, 242-247 (2003).
262. Sepcic J, Mesaros E, Materljan E, Sepic-Grahovac D. Nutritional factors and multiple sclerosis in Gorski Kotar, Croatia. Neuroepidemiology 12, 234-240 (1993).
263. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morriset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int. J. Epidemiol. 27, 845-852 (1998).
264. Smirnova NF, Boiko AN, Deomina TL, Gusev EI. Smoked meat is the main environmental risk factor in Moscow population: data of a new case-control study. Mult. Scler. 3, 285 (1997).
265. Lauer K, Geilenkeuser M, Wahl A, Firnhaber W, Claus D. The intake of selected foods in multiple sclerosis: a possible interaction with late childhood infections. Mult. Scler. 14(Suppl. 1), 189 (2008).
266. Zhang SM, Willett WC, Hernán MA, Olek MJ, Ascherio A. Dietary fat in relation to risk of multiple sclerosis among two large cohorts of women. Am. J. Epidemiol. 152, 1056-1064 (2000).
267. Pugliatti M, Casetta I, Cossu P et al. An international case-control study of risk factors for multiple sclerosis. Mult. Scler. 140(Suppl. 1), 197 (2008).
268. Lauer K. A possible paradox in the immunology of multiple sclerosis: its apparent lack of 'specificity' might provide clues to the etiology. Med. Hypotheses 40, 368-374 (1993).
269. Knowles ME, Gilbert J, McWeeny DJ. Phenols in smoked, cured meats: nitrosation of phenols in liquid smokes and smoked bacon. J. Sci. Food Agr. 26, 267-276 (1975).
270. Chen LB, Issenberg P. Interactions of some wood smoke components with e aminogroups in proteins. J. Agric. Food Chem. 20, 1113-1115 (1972).
271. Achtnich M, Zoeller M. Autoreactive ntibodies in thymus and spleen of neonatal and young adult BALB/c mice: influence of prenatal tolerization. Scand. J. Immunol. 33, 25-36 (1991).
272. Weltzien HU, Moulon C, Martin S, Padovan E, Hartmann U, Kohler J. T cell immune responses to haptens. Structural models for allergic and autoimmune reactions. Toxicology 107, 141-151 (1996).
273. Lauer K. The risk of multiple sclerosis in the U.S.A. in relation to sociogeographic features: a factor-analytical study. J. Clin. Epidemiol. 47, 43-48 (1994).
274. Bates D, Cartlidge NE, French JM et al. A double-blind controlled trial of long-chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 52, 18-22 (1989).
275. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis. Observations from Norway. Neuroepidemiology 30, 140-146 (2008).
276. Achiron A, Barak Y, Shmuel M, Izhak Y, Faibel M, Edelstein S. Alfacalcidol treatment in multiple sclerosis. Clin. Neurophamacol. 26, 53 (2003).
277. Wingerchuk DM, Lesaux J, Rice GPA, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitramin D3) for relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 76, 1294-1296 (2005).
278. Darmstaedter E, Firnhaber W, Lauer K. Food consumption in Lower Saxony, northern Germany, in relation to the multiple sclerosis mortality 1975-1995: an ecological study. Presented at Conference of German Society of Epidemiology, Muenster, Germany, September 16-19 (2009).
279. Wender M, Kazmierski R. The descriptive and analytical epidemiology of multiple sclerosis in Western Poland. In: Multiple Sclerosis in Europe. An Epidemiological Update. Firnhaber W, Lauer K (Eds). LTV Press, Germany, 241-248 (1994).
280. Zhang SM, Hernán MA, Olek MJ, Spiegelman D, Willet WC, Ascherio A. Intakes of carotenoids, vitamin C, and vitamin E and MS risk among two large cohorts of women. Neurology 57, 75-80 (2001).
281. Fitzgerald G, Harbige LS, Forti A, Crawford MA. The effect of nutritional counselling on diet and plasma EFA status in multiple sclerosis patiens over 3 years. Hum. Nutr. Appl. Nutr. 41A, 297-310 (1987).
282. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. AICR, DC, USA (2000).
283. Kleinbaum DG, Klein M. Logistic Regression. A Self-learning Text. Springer, NY, USA (2002).
284. *1501 and Epstein-Barr virus in multiple sclerosis. Neurology 70, 1113-1118 (2008).
285. Cocco E, Sardu C, Murru R et al. Multiple sclerosis risk: interaction between human leukocyte antigen and the environment in Sardinian population. Mult. Scler. 15, 1030-1036 (2009).
286. *1501 interact as risk factors for multiple sclerosis. J. Neuroimmunol. 215, 102-107 (2009).
287. Martínez A, Álvarez-Lafuente R, Mas A et al. Environment-gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TA. Hum. Immunol. 68, 695-689 (2007).
288. Dickinson JL, Perera DI, van der Mei AF et al. Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor variant in this interaction. Mult. Scler. 15, 563-570 (2009).
289. Marrie RA. When one and one make three. HLA and EBV infection in MS. Neurology 70, 1067-1068 (2008).
290. Simon KC, van der Mei I, Munger KL et al. Smoking as an independent risk factor for multiple sclerosis: considering possible combined effects with the human leucocyte antigen DR15 genotype and anti-EBNA antibody titers. Mult. Scler. 14 (Suppl. 1), 200 (2008).
291. Lukes RJ, Cox FH. Clinical and morphological findings in 30 fatal cases of infectious mononucleosis. Am. J. Pathol. 34, 586 (1958).
292. Sheehy TW, Artenstein MS, Green RW. Small intestinal mucosa in certain viral diseases. JAMA 190, 1023-1028 (1964).
293. Lucas RM, Ponsonby A-L, McMichael AJ et al. Observational analytical studies in multiple sclerosis: controlling bias through study design and conduct. The Australian Multicentre Study of Environment and Immune Function. Mult. Scler. 13, 827-839 (2007).
294. Greenberg B, Goins J, Frohman E et al. Establishment of a large scale, multidisciplinary sample and data repository for determining genetic and environmental causes of multiple sclerosis. Mult. Scler. 13, S93 (2007).
295. Flachenecker P, Stuke K. National MS registries. J. Neurol. 255(Suppl. 6), 102-108 (2008).
296. Lauer K. Divergent risk of multiple sclerosis in two anabaptist communities in America. Med. Hypotheses 67, 969-974 (2006).
297. Lauer K. Multiple sclerosis frequency in Israel's diverse populations. Neurology 68, 311 (2007).
298. Lauer K. The association of the multiple sclerosis mortality 1965-1994 in Canada with food retail trade and food-related occupations: an ecological study. Neuroepidemiology 33, 198 (2009).
299. Lauer K. Food consumption in northern and southern States of the USA: an ecological study on the risk of multiple sclerosis in space and time. Mult. Scler. 15(Suppl. 2), 44 (2009).